Plazomicin
Zemdri (plazomicin) is a small molecule pharmaceutical. Plazomicin was first approved as Zemdri on 2018-06-25. It is used to treat escherichia coli infections, pyelonephritis, and urinary tract infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Zemdri
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zemdri (plazomicin) | New Drug Application | 2024-12-20 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PLAZOMICIN SULFATE, ZEMDRI, CIPLA USA | |||
| 2028-06-25 | GAIN | ||
| 2023-06-25 | NCE | ||
HCPCS
Code | Description |
|---|---|
| J0291 | Injection, plazomicin, 5 mg |
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | 2 | — | — | 3 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | 2 | — | — | 3 |
| Communicable diseases | D003141 | — | — | — | 1 | 2 | — | — | 3 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 1 | 2 | — | — | 3 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | 1 | — | — | 1 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 1 | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | 1 | — | — | 1 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 1 | — | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Plazomicin |
| INN | plazomicin |
| Description | Plazomicin, sold under the brand name Zemdri, is an aminoglycoside antibiotic used to treat complicated urinary tract infections. As of 2019 it is recommended only for those in whom alternatives are not an option. It is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | antibiotics (Micromonospora strains) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O |
Identifiers
| PDB | — |
| CAS-ID | 1154757-24-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1650559 |
| ChEBI ID | — |
| PubChem CID | 42613186 |
| DrugBank | DB12615 |
| UNII ID | LYO9XZ250J (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 985 documents
View more details
Safety
Black-box Warning
Black-box warning for: Zemdri (plazomicin)
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use